Unfortunately, clinical evaluation and diagnostic tests sometimes fail to determine whether a necrotizing myopathy is immune mediated, resulting in undertreatment of autoimmune myopathies or ...

YTS-109 is under clinical development by Bristar Immunotech Biotechnology and currently in Phase I for Polymyositis.

YTS-109 is under clinical development by Bristar Immunotech Biotechnology and currently in Phase I for Dermatomyositis.

Geode Capital Management LLC boosted its stake in shares of Cabaletta Bio, Inc. (NASDAQ:CABA – Free Report) by 12.8% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 1,094 ...

After hours: January 3 at 4:27:10 PM EST Loading Chart for ACIU ...

The anti-SRP myopathy was compared with myopathology in other types of inflammatory and immune myopathies. Results: The patients with anti-SRP antibodies developed weakness at ages ranging from 32 to ...

After hours: 7:46:48 pm GMT-5 ...